A week after finishing pivotal trials with its nausea drug, Hana Biosciences Inc. signed a letter of intent to double its pipeline of compounds by licensing worldwide rights to three targeted chemotherapeutics from Inex Pharmaceuticals Corp. in a stock-and-cash deal worth up to $42 million. (BioWorld Today) Read More
